Ozempic (known as Rybelsus) is a prescription medication containing semaglutide. It belongs to the class of glucagon-like peptide-1 receptor agonists. The drug is used to improve blood-glucose control in adults with type 2 diabetes. It is also approved to reduce the risk of major cardiovascular events in eligible patients. Ozempic works by activating glp-1 receptors in the pancreas to increase insulin release when glucose levels rise. Activation of these receptors also suppresses glucagon secretion, lowering blood glucose. Additionally, the medication slows gastric emptying and modestly reduces appetite, which can lead to weight loss. The combined effects result in better glycemic control and decreased cardiovascular risk.

Ozempic (known as Rybelsus) is a medication used to improve blood sugar control in adults with type 2 diabetes. It contains semaglutide, a synthetic version of a hormone that regulates insulin release. It works by mimicking the hormone to stimulate insulin secretion when blood glucose is high. It also reduces the amount of glucose produced by the liver. It slows gastric emptying, which helps lower post-meal blood sugar. The drug is taken orally, absorbed through the intestine, and reaches the bloodstream to act on target cells. Its prolonged effect allows once-weekly dosing, providing sustained glucose lowering without frequent injections.

Ozempic, also marketed as rybelsus, can cause gastrointestinal disturbances such as nausea and diarrhea. Some users experience reduced appetite which may affect nutritional intake. Constipation and abdominal discomfort are also documented side effects. Headache and fatigue may occur in certain individuals. Rarely, the medication is linked to gallbladder problems and pancreatitis. Animal studies indicate a potential risk of thyroid c-cell tumors. The frequency and severity of these effects can vary among patients. Tracking symptoms can help understand personal response.

Ozempic known as rybelsus is a medication used for type 2 diabetes and chronic weight management. Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Some users experience reduced appetite which may affect nutritional intake. Rare but serious adverse events such as pancreatitis and gallbladder disease have been reported. In clinical studies a small number of patients developed kidney impairment requiring monitoring. Fatigue and headache are also listed among less frequent reactions observed during treatment.